Matching or genetic engineering of HLA Class I and II facilitates successful allogeneic 'off-the-shelf' regulatory T cell therapy (2023)
Attributed to:
University of Oxford Confidence in Concept – Round 7
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1101/2023.08.06.551956
Publication URI: http://dx.doi.org/10.1101/2023.08.06.551956
Type: Preprint